Baxter International’s Baxter Healthcare subsidiary has acquired certain assets related to PerClot Polysaccharide Hemostatic System (PHS) from CryoLife in a deal valued at up to $60.8m.

The transaction includes $25m paid upfront, with the remainder to be paid after the achievement of certain select milestones.

Of the total amount, CryoLife will receive up to $45.8m and Starch Medical (SMI) will receive the remaining $15m.

Additionally, CryoLife and SMI agreed to end their existing PerClot licensing and supply agreements.

Under the deal, Baxter acquired the PerClot product line along with the worldwide marketing rights, customer relationships, intellectual property and equipment.

Baxter stated that the acquisition marks its entry into the global hemostatic powder segment as well as the expansion of its advanced surgery portfolio to include a wider range of active and passive solutions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With sales in more than 35 countries across the world, PerClot has a global commercial presence but is not currently cleared for sale in the US.

Baxter advanced surgery business president Wil Boren said: “The addition of PerClot further enhances our ability to optimise patient care by addressing a broad range of intraoperative bleeding with both active and passive hemostatic solutions, helping surgeons to use the right product for the right bleed.

“PerClot launches Baxter into the attractive hemostatic powder segment while expanding our surgical offerings and complementing our recent acquisition of Seprafilm Adhesion Barrier.”

By absorbing water from the blood, PerClot produces a gelled matrix that sticks to, and also forms a mechanical barrier, with the bleeding tissue.

The company noted that PerClot PHS is used in surgical procedures, excluding neurological and ophthalmic, and is not recommended when infection is suspected.

It is a single-use product and should not be used to control post-partum bleeding or menorrhagia.